David E. Gauden, DPhil
David was a co-founder of our sister company Blue Earth Diagnostics. As Chief Scientific Officer, and later Chief Executive Officer, he was instrumental in building the company from a start-up in 2014 to a successful leader in nuclear medicine and molecular imaging prior to its acquisition by Bracco Imaging in 2019. David also led the spin-out of Blue Earth Therapeutics from Bracco in 2021. Prior to founding Blue Earth Diagnostics, David was Product Leader for Oncology Molecular Imaging at GE Healthcare. With more than 25 years in the radiopharmaceuticals industry, David has deep experience across the field. He has a degree in biotechnology from Warwick University and a doctorate in biochemistry from Oxford University.
Chelsea Roche
Chelsea is an intellectual property lawyer with commercial, corporate, litigation and governance experience, and is dual qualified as an English Solicitor and Australian Legal Practitioner. Previously she was General Counsel and a core member of the Executive team for Blue Earth Diagnostics and has considerable experience supporting translational research and funding activity. She started her career as a Nuclear Medicine Technologist and has several years’ experience at international law firms advising life sciences clients and serves as Trustee for the Institute of Physics and Engineering in Medicine and is a member of the BioIndustry Association Intellectual Property Advisory Committee.
Bradley Waldron
Brad is a CMC specialist with deep experience in development, manufacturing, and supply of radiopharmaceuticals. He was previously CMC Lead for diagnostic and therapeutic radiopharmaceuticals at IPSEN/OctreoPharm Sciences. Brad has a doctorate in Chemistry from Durham University and completed post-doctoral studies in radiopharmaceutical development at Johannes Gutenberg University.
Robert Dann
Robert has worked on developing novel therapeutics, diagnostics and applications for cancer care for much of his career, primarily in global product strategy and strategic marketing roles. He started his healthcare career at AstraZeneca where he took three cancer therapeutics each to >$1B revenues. At GE Healthcare he led global oncology marketing and drove the launches of several new oncology diagnostics. More recently he has held oncology strategy and leadership roles at IBM Watson Health and at start-up biotechs. He has also participated in several corporate acquisitions and investment rounds. He has an MBA from Columbia University and a Master’s in Russian Civilization from the University of Chicago.
Dr Julian Howell
Dr Julian Howell is a pharmaceutical physician with over 25 years of international biopharmaceutical leadership experience spanning early research through global product approval and commercialisation. He has held Chief Medical Officer, Chief Executive and senior executive positions within biotechnology and specialty pharmaceutical companies including ReNeuron, Shield Therapeutics, ProStrakan/Kyowa Kirin and Roche, leading multidisciplinary teams across clinical development, medical affairs, pharmacovigilance and regulatory strategy. During his career he has contributed to multiple successful FDA and EMA approvals across oncology, haematology, neurology and rare diseases, and has extensive experience of regulatory interactions, fundraising, licensing and investor engagement. Dr Howell holds an MBA from Cranfield University, is a Fellow of both the Faculty of Pharmaceutical Medicine and Royal College of Surgeons. His background combines deep scientific expertise with strategic commercial leadership and extensive experience of building value in emerging biotechnology companies.
David was a co-founder of our sister company Blue Earth Diagnostics. As Chief Scientific Officer, and later Chief Executive Officer, he was instrumental in building the company from a start-up in 2014 to a successful leader in nuclear medicine and molecular imaging prior to its acquisition by Bracco Imaging in 2019. David also led the spin-out of Blue Earth Therapeutics from Bracco in 2021. Prior to founding Blue Earth Diagnostics, David was Product Leader for Oncology Molecular Imaging at GE Healthcare. With more than 25 years in the radiopharmaceuticals industry, David has deep experience across the field. He has a degree in biotechnology from Warwick University and a doctorate in biochemistry from Oxford University.
Chelsea is an intellectual property lawyer with commercial, corporate, litigation and governance experience, and is dual qualified as an English Solicitor and Australian Legal Practitioner. Previously she was General Counsel and a core member of the Executive team for Blue Earth Diagnostics and has considerable experience supporting translational research and funding activity. She started her career as a Nuclear Medicine Technologist and has several years’ experience at international law firms advising life sciences clients and serves as Trustee for the Institute of Physics and Engineering in Medicine and is a member of the BioIndustry Association Intellectual Property Advisory Committee.
Brad is a CMC specialist with deep experience in development, manufacturing, and supply of radiopharmaceuticals. He was previously CMC Lead for diagnostic and therapeutic radiopharmaceuticals at IPSEN/OctreoPharm Sciences. Brad has a doctorate in Chemistry from Durham University and completed post-doctoral studies in radiopharmaceutical development at Johannes Gutenberg University.
Robert has worked on developing novel therapeutics, diagnostics and applications for cancer care for much of his career, primarily in global product strategy and strategic marketing roles. He started his healthcare career at AstraZeneca where he took three cancer therapeutics each to >$1B revenues. At GE Healthcare he led global oncology marketing and drove the launches of several new oncology diagnostics. More recently he has held oncology strategy and leadership roles at IBM Watson Health and at start-up biotechs. He has also participated in several corporate acquisitions and investment rounds. He has an MBA from Columbia University and a Master’s in Russian Civilization from the University of Chicago.
Dr Julian Howell is a pharmaceutical physician with over 25 years of international biopharmaceutical leadership experience spanning early research through global product approval and commercialisation. He has held Chief Medical Officer, Chief Executive and senior executive positions within biotechnology and specialty pharmaceutical companies including ReNeuron, Shield Therapeutics, ProStrakan/Kyowa Kirin and Roche, leading multidisciplinary teams across clinical development, medical affairs, pharmacovigilance and regulatory strategy. During his career he has contributed to multiple successful FDA and EMA approvals across oncology, haematology, neurology and rare diseases, and has extensive experience of regulatory interactions, fundraising, licensing and investor engagement. Dr Howell holds an MBA from Cranfield University, is a Fellow of both the Faculty of Pharmaceutical Medicine and Royal College of Surgeons. His background combines deep scientific expertise with strategic commercial leadership and extensive experience of building value in emerging biotechnology companies.
Contact Us
Magdalen Centre
Robert Robinson Avenue
The Oxford Science Park, Oxford
OX4 4GA, UK
